Ozempic for all? We might be closer than you think.

Economist Emily Oster joins Michael Smerconish to discuss the growing debate over whether Medicare and Medicaid should cover GLP-1 weight-loss drugs like Ozempic. With prices dropping and evidence mounting that they reduce long-term health costs, are we nearing a point where coverage pays for itself?